Niro Attys Again Face Sanctions In Sloan-Kettering IP Row

By Daniel Siegal · January 18, 2017, 10:23 PM EST

A New York federal judge ruled Wednesday that a biopharmaceutical company can refile its suit seeking to reclaim gene therapy patent rights from the Sloan-Kettering Institute in state court, but said...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order on Motion to Dismiss/Lack of Jurisdiction Order on Motion for Leave to File Document

Case Information

Case Title

Errant Gene Therapeutics, LLC et al v. Sloan-Kettering Institute for Cancer Research

Case Number

Court

New York Southern

Nature of Suit

Patent

Date Filed

March 18, 2015

Recent Articles By Daniel

August 12, 2020
J&J Asks Mo. High Court To Overturn $2.1B Talc Ruling
July 29, 2020
J&J Can't Get Missouri Court To Reconsider $2.1B Talc Ruling
June 26, 2020
J&J Put In A Corner By Court That Slashed $4.7B Talc Verdict
June 11, 2020
No New Trial For Jockey In Career-Ending Spinal Surgery Suit
June 01, 2020
Asbestos Battles Show One Possible Fate For J&J After Talc
April 28, 2020
J&J Talc Users Get One More Shot At False Ad Class Action
April 27, 2020
J&J Can't Boot Experts To Sink Asbestos-In-Talc MDL
April 24, 2020
J&J's Efforts To Toss $4.7B Talc Verdict Get Mixed Reception
April 21, 2020
How J&J's $4.7B Appeal Could Shape Missouri's Talc Trials
April 01, 2020
Justice Delayed: Coronavirus Halts Opioid, Cancer Trials